Table 1.
Summary of Zika vaccines in clinical trials
| Vaccine | Adjuvant | Developer | Regimen (weeks/route) | Phase | Clinical trial | Publication |
|---|---|---|---|---|---|---|
| GLS-5700 Synthetic ZIKV prM/E |
None | Inovio and Gene One Life Sciences | 1, 2 mg/ID 2 mg/ID |
1 |
NCT02809443 NCT02887482 |
Ref. 3 |
| VRC-ZKADNA085-00-VP | None | NIH/VRC | 0 + 8, 0 + 12, 0 + 4 + 8, 0 + 4 + 20 4 mg/IM/both arms |
1 | NCT02840487 | Ref. 5 |
| VRC-ZKADNA090 -00-VP ZIKV wt prM/E |
None | NIH/VRC | 0 + 4 + 8 4 mg/IM Needle vs. PharmaJet |
1 | NCT02996461 | Ref. 5 |
| VRC-ZKADNA090-00-VP ZIKV wt prM/E |
None | NIH/VRC | 0 + 4 + 8 4 mg vs. 8 mg/ IM/Both arms PharmaJet |
2 | NCT03110770 | |
| Inactivated ZIKV (MR8766) | Alum | Bharat Biotech | 0 + 30 days 2.5 vs. 5 vs. 10 µg |
1 | CTRI/2017/05/008539 | |
| Inactivated ZIKV (VLA 1601) |
Alum | Valneva (+Emergent Biosolutions) | 0 + 1 vs. 0 + 4 3 vs. 6 antigen units |
1 | NCT 03425149 | |
| Zika purified inactivated vaccine [ZPIV] | Alum | WRAIR | 0, 0 + 1, 0 + 2, 0 + 4 5 µg/IM 0 + 4 2.5 vs. 5 vs. 10 mg/IM 0 + 4 5 µg/IM (Puerto Rico) 0 + 4 5 µg/IM (±YF Vax; ±Ixario) ZPIV booster at 1 year |
1 |
NCT02937233 NCT02952833 NCT03008122 NCT02963909 |
Ref. 4 |
| Inactivated ZIKV (TAK-426) |
Alum | Takeda | 0 + 4 2 vs. 5 vs. 10 µg/IM |
1 | NCT03343626 | |
| Live Measles virus-Zika [MV-Zika] | None | Themis | Low vs. high dose 0 vs. 0 + 4 |
1/2 | NCT02996890 | |
| mRNA | None | Valera/Moderna | mRNA-1325 | 1/2 | NCT03014089 |
ID intradermal, IM intramuscular